Safety of newly approved drugs: Implications for prescribing

JAMA

Volumn 287, Issue 17, 2002, Pages 2273-2275

  Temple, Robert J ^a   Himmel, Martin H ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; AZARIBINE; BENOXAPROFEN; BEPRIDIL; BROMFENAC; CLOZAPINE; CYCLOSPORIN; DANAZOL; ENCAINIDE; FELBAMATE; FLECAINIDE ACETATE; FLOSEQUINAN; ISOTRETINOIN; KETOCONAZOLE; KETOROLAC; LAMOTRIGINE; METOPROLOL; MIDAZOLAM; MORACIZINE; NEW DRUG; PEMOLINE; PROPAFENONE; SUPROFEN; TEMAFLOXACIN; TIENILIC ACID; TOCAINIDE; TOLCAPONE; TROGLITAZONE; ZALCITABINE; ZOMEPIRAC;

DRUG APPROVAL; DRUG LABELING; DRUG SAFETY; EARLY DIAGNOSIS; EDITORIAL; LABELING INDEX; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL;

EID: 0036569927     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.287.17.2273     Document Type: Editorial

References (4)

1. Timing of new black box warnings and withdrawals for prescription medications
2. Mortality and morbidity in patients receiving encainide, flecainide, or placebo
3. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction
4. Requirements on context and format of labeling for human prescription drugs and biologics; requirements for prescription drug products